FOOD COMPOSITION AND ADDITIVES GMOtrack: Generator of Cost-Effective GMO Testing Strategies PETRA KRALJ NOVAK Jo ef Stefan Institute, Department of Knowledge Technologies, Jamova 39, 1000 Ljubljana, Slovenia KRISTINA GRUDEN andDANY MORISSET National Institute of Biology, Department of Biotechnology and Systems Biology, Ve na pot 111, 1000 Ljubljana, Slovenia. Mark Tullij Ciceron. Tri traktata ob oratorskom iskusstve. Moskva: Nauka, 1972. Bivalentnist rymskoyi pravovoyi diysnosti.

This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment with sitagliptin used as part of usual care compared to usual care without sitagliptin in participants with type 2 diabetes mellitus (T2DM) having a history of cardiovascular (CV) disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%. Primary hypothesis A is that sitagliptin, when used as part of usual care, is non-inferior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint of Major Adverse Cardiovascular Event (MACE) plus.

If hypothesis A is satisfied: hypothesis B is that sitagliptin, when used as part of usual care, is superior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Sitagliptin Drug: Placebo Phase 3. Layout table for study information Study Type: Interventional (Clinical Trial) Actual Enrollment: 14671 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Actual Study Start Date: December 10, 2008 Actual Primary Completion Date: March 30, 2015 Actual Study Completion Date: March 30, 2015. Layout table for additonal information Responsible Party: Merck Sharp & Dohme Corp. ClinicalTrials.gov Identifier: Other Study ID Numbers: 0431-082 2008_523 ( Other Identifier: Merck study number ) 2008-006719-20 ( EudraCT Number ) First Posted: November 13, 2008 Results First Posted: April 15, 2016 Last Update Posted: August 17, 2018 Last Verified: July 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Plan Description: URL: Additional relevant MeSH terms.

Opera omnia, 1566 Sitseron Mark Tulliy (Marcus Tullius Cicero) (mil. 106.3.1, Arpinum — mil. 43.7.12, hozirgi Gaeta yaqini) — Rim siyosiy arbobi, notiq, yozuvchi.

Rimda tahsil olib, notiqlik sanʼatini egallaydi, soʻng Afina, Kichik Osiyo va Rodosda oʻz bilimini mukammallashtiradi. Elchilik davrida (mil. 63 y.) Katalina fitnasini fosh etgani uchun 'fuqarolik chambari' bilan tadkirlanadi va Rim fukarolari orasida birinchi boʻlib 'Yurt otasi' unvoniga sazovor boʻladi. Hara hara mahadeva shambo shankara serial mp3 songs.

Ammo rimlik fitnachilarni sudsiz qatl etgani sababli mil. 58 yilda quvgʻinga uchrab, xorijda yashashga majbur boʻlgan.

Sezar oʻddirilgach (mil. 44 y.), Antoniy buyrugʻi bilan qatl etilguniga qadar Rimning amaldagi hukmdori sanalgan. Siyosat, falsafa va adabiyotda 'oʻrta oqim' hisoblangan barqarorlik va vazminlik aqidalariga sodiq boʻlgan. 'Aralash davlat tuzilmasi' (monarxiya, aristokratiya va demokratiyaning qoʻshilishidan paydo boʻlgan hokimiyat) S.ning siyosiy ideali boʻlib, mil. 2-asr boshidagi Rim respublikasini buning namunasi deb hisoblagan.

Faylasuf sifatida atomizmta qarshi chiqdi, jonni oʻlmas va abadiy deb bildi, real tasavvurlarni real boʻlmagan tasavvurlardan farq qilish uchun mezon yoʻq deb hisobladi. Falsa-fiy asarlarida etika masalalariga asosiy eʼtiborni qaratdi. Yunon falsafasi atamalarini ishlab chiqdi.